💊

Thiotepa Riemser

thiotepa

Hematopoieettinen kantasolusiirto;kasvaimet

✅ Valtuutettu Yleinen

✅

Ei aktiivisia hälytyksiä

Tällä lääkkeellä ei ole meneillään olevia puutoksia, turvallisuuskirjeitä eikä takaisinottoja.

Mihin sitä käytetään

Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients

⚠️ Potilasturvallisuus

EMA:n virallinen sivu

https://www.ema.europa.eu/en/medicines/human/EPAR/thiotepa-riemser